Antinuclear and Anti-dsDNA Antibodies Might Predict Anti–TNF-α Treatment Failure

But routine screening in treatment recipients ain't necessarily necessary.

Many patients treated with TNF antagonists for psoriasis develop antinuclear antibodies (ANAs), and some develop anti–double-stranded DNA antibodies (anti-dsDNAs). The clinical relevance and underlying mechanism of these developments are unknown. Antibody formation seems to occur especially frequently in infliximab recipients regardless of the indication. Researchers retrospectively examined follow-up data for 97 TNF antagonist recipients to see whether treatment failure was associated with antibody development.

The patients received infliximab, adalimumab, or etanercept therapy for psoriasis; 60 were on their first agent, 22 had been on and stopped one agent, 9 had been on and stopped two agents, and 6 had been on and stopped all three agen…

Reviewing Author

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)